美国B型血友病的医疗资源利用与费用负担
基于IBM MarketScan数据库(2011年6月至2019年2月),采用理赔算法将454例成年男性B型血友病患者分为4种临床特征,并与1:1人口学匹配的对照比较。B型血友病患者合并症负担和医疗资源利用显著更高,年均总医疗费用超过对照的25倍,且费用随严重程度增加而升高。
要点
- B型血友病患者住院、急诊和门诊就诊次数均显著高于对照。
核心结论
- B型血友病与美国医疗系统显著的经济负担相关,费用随疾病严重程度增加而升高。
研究设计与样本
- 基于IBM MarketScan数据库(2011年6月至2019年2月)的回顾性索赔分析,纳入454例成年男性B型血友病患者和1:1人口学匹配的454例对照。
主要发现
- B型血友病患者Charlson合并症指数均值±SD为0.9±1.7,显著高于对照的0.3±0.9(P < .001)。
- B型血友病患者住院0.3±0.6次、急诊0.6±1.2次、门诊17.7±22.9次,均显著高于对照(分别为0.1±0.3、0.2±0.6、8.0±11.0,所有P < .001)。
临床怎么用
- 临床应关注B型血友病患者的合并症管理和医疗资源使用,尤其是重度患者的高费用负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia B is a rare congenital blood disorder characterized by factor IX deficiency. Clinical profiles of hemophilia B range from mild to severe forms of the disease. The objective of this study was to characterize the economic burden associated with differing clinical profiles of hemophilia B from a US health system perspective. Using the IBM MarketScan database (June 2011-February 2019), a claims-based algorithm was developed to identify 4 distinct profiles (mild, moderate, moderate-severe, and severe) in adult males with hemophilia B based on the frequency of hemorrhage events and factor IX replacement claims. Mean annual health care resource use (HRU) and costs were statistically compared between patients with hemophilia B (N = 454) and 1:1 demographic-matched controls (N = 454), both overall and with stratification by clinical profile. Compared with matched controls, patients with hemophilia B had a significantly higher comorbidity burden (Charlson Comorbidity Index, mean ± standard deviation [SD]: 0.9 ± 1.7 vs 0.3 ± 0.9, P < .001). Across all clinical profiles, patients with hemophilia B had significantly higher HRU vs matched controls (mean ± SD: 0.3 ± 0.6 vs 0.1 ± 0.3 inpatient admissions; 0.6 ± 1.2 vs 0.2 ± 0.6 emergency department visits; 17.7 ± 22.9 vs 8.0 ± 11.0 outpatient visits; all P < .001). Annual total health care costs per patient among patients with hemophilia B were more than 25-fold higher vs matched controls (mean ± SD: $201 635 ± $411 530 vs $7879 ± $29 040, respectively, P < .001). Annual total health care costs per patient increased with increasing severity (mean ± SD: mild, $80 811 ± $284 313; moderate, $137 455 ± $222 021; moderate-severe, $251 619 ± $576 886; severe, $632 088 ± $501 270). The findings of this study highlight the substantial burden of illness associated with hemophilia B.
引用
- Buckner TW, Bocharova I, Hagan K, et al. Health care resource utilization and cost burden of hemophilia B in the United States. Blood Adv. 2021. PMID: 33830206. doi:10.1182/bloodadvances.2020003424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。